Form 4 Filing for Kevin Robert Lind

Kevin Robert Lind, a director at Avalo Therapeutics, Inc. (AVTX), was granted 1352 stock options on September 30, 2026. These options, with an exercise price of $15.33, are fully vested and were issued under the company's Amended and Restated Non-Employee Director Compensation Plan in lieu of board fees. The options have an expiration date of September 30, 2036. The transaction is reported on Form 4, with a transaction code "A" indicating acquisition. Mr. Lind acquired these options directly, and post-transaction, he holds 1352 shares underlying these options. The grant price was $12.29 per share.